amgen

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included top mining stocks and a Detroit automaker. Bearish calls featured biotech stocks and a key cloud player. Rising concerns about a trade war, another interest rate increase and a social...

Benzinga has featured a look at many investor favorite stocks over the past week. Bullish calls featured the e-commerce leader and a social media giant. Bearish calls included the iPhone maker and a struggling industrial giant. With earnings reporting season in full swing, and as the World...

Shares of Amgen, Inc. (NASDAQ: AMGN) fell 7 percent after the biotechnology company released data from its therapy called Repatha, which is used to lower the risk of heart attacks, strokes and heart problems. Amgen reported Repatha reduces the risk of heart attacks, stokes and other heart-related...

This weekend's Barron's offers the outlook for a private equity giant and a leading online travel booker. The prospects for a biotech giant and a struggling bookseller are also examined. Another featured article offers a look at how Barron's small-cap stock picks for 2016...

This weekend's Barron's takes a look at 10 dividend stocks with hefty yields and the best prospects for growth. The prospects for a leading fertilizer maker and a software security pioneer are also examined. Other featured articles ponder the prospects for a top gold mining stock and a modular...

The cover story in this weekend's Barron's offers tips and strategies from the panelists at the latest income roundtable. Safe yields of up to 5 percent can be locked in with careful portfolio construction, says veteran fixed-income investors and a dividend stock pro. Another featured article...

This weekend's Barron's ponders the prospects for a leading auto services provider and a financial services technology star. Prospects for two small-cap banks with strong fundamentals are also examined. Other featured articles take a look at what bears such as Bill Gross and...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of both of these stocks rose sharply during the two-week period. Short sellers shied away from many of the...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of one of those two stocks slumped more than 22 percent during the period. Short sellers shied away from many of...

Short interest in many leading biotech stocks declined in the most recent period. Bucking that trend is a biotech company that soon will be acquired by an overseas peer. Short sellers retreated most sharply from a biotech that some analysts now see as a value stock. Between the March 31 and April...